Dr. Saeid Ghavami completed his undergraduate training in 1989 (Shiraz University, Shiraz, Iran), MSc and PhD (1995, 2004, TMU University, Tehran, Iran) in clinical biochemistry.

His postdoctoral training was focused on the application of apoptosis/autophagy/unfolded protein response (UPR) in the regulation of cell fate.

His research program is focused on the regulation of cellular phenotype via targeting autophagy and UPR at the Department of Human Anatomy and Cell Science, University of Manitoba.

He has been the recipient of a number of prestigious awards including the CIHR/GSK/CLA postdoctoral award (No. 1 in Canada, 2007), Parker B Francis Career Development Award (top 10 in North America, 2009), ATS Science and Innovation Center Rising Star of Research Award (2017), CIHR/CCS/OICR Early Career Research Award (2017).

Dr. Ghavami is currently an honorary professor and co-founder of the Autophagy Research Centre at Shiraz University of Medical Science and Tehran University of Medical Sciences, and an honorary professor at Katowice School of Technology, Poland.

He is the associate editor of BBA-Mol Basis of Disease, Molecular Neurobiology, BB Reports and IJMS.

Cross-appointments

• Honorary professor and co-founder, Autophagy Research Centre, Shiraz University of Medical Science

• Honorary professor and co-founder, Autophagy Research Centre, Tehran University of Medical Sciences

• Honorary professor, Katowice School of Technology, Poland

Scopus: > 20,400 citations, h- index: 60

Google Scholar: > 29,600 citations, h-index: 69

Fundamentally, my research program is built on my expertise in the genetics of autophagy and cellular plasticity. My experience and expertise in this area have resulted in my being ranked among the top 2% of scientists since 2019, according to the Web of Science. I have established myself as an internationally known scientist in the field of autophagy locally, nationally and internationally. According to the scientist evaluation website ExpertScape, I am currently ranked a top autophagy researcher both at the University and nationally in Canada, and I am ranked among the top 50 autophagy scientists worldwide.

My top 5 highest-impact research contributions are outlined here.

1.  Identifying the role of autophagy in the regulation of apoptosis 

(a) I discovered that autophagy controls the fate of mammalian cells via regulation of intrinsic apoptosis (Biology, 2023, Cells, 2021& 2020, FEBS. J., 2020, Cell Death Discovery, 2018, World J Gastroenterology, 2015). My discoveries increased our understanding of how autophagy determines cell survival under stress conditions. 

(b) My team recently discovered a role for casein kinase 1-α (CK1α) and the AKT pathway in regulating autophagy flux and the effect of this on the response of mammalian cells to 5-fluorouracil (5FU)-mediated apoptosis. This finding represents a novel mechanism of autophagy flux in the regulation of DNA damage-induced apoptosis (Arch Immunol Ther Exp 2021, C.J.P.P. 2021). 

(c) We discovered the autophagy activities of N-TiO2 nanoparticles in mammalian cells (Sci Rep 2016). These findings provided a deep understanding of the effects of nanoparticles on mammalian cellular organelles (mitochondria and lysosomes).

2.  Regulation of the cellular phenotype by autophagy 

(a) We discovered the impact of autophagy on the secretory phenotype of rat astrocytes and the secretion of chondroitin sulphate proteoglycans (CSPG; Mol Neurobiol 2021). We also discovered that autophagy regulates the extracellular matrix in murine cerebellar development (BB Reports, 2022). We also discovered the impact of autophagy on the regulation of synthesis phenotypes of atrial fibroblasts (Cell Death Discovery 2015) and IPF fibroblasts (AJP-Lung, 2018), both of which have opened a new vision of mechanisms of fibrotic diseases in humans. 

(b) We discovered that autophagy correlates with components of lung function in humans, which could have applications in non-invasive biomarkers for diagnosis of lung tissue injury from lung function data. We were able to show that autophagy directly affects FEV1, FVC, TLC, and RV while autophagosome formation is associated with increased diffusion capacity (DLCO), an indicator of alveolar-capillary membrane function (Cells 2021). 

(c) In collaboration with a team in Italy, we discovered the impact of the cytokine TNFα in regulating autophagy flux and secretory phenotype in human corneal fibroblasts. This finding has a potential impact in developing medication to target autophagy flux to control ocular allergic inflammation (JACI, 2020). 

(d)  Our investigations have shown that autophagy (BBA-Mol Cell Res 2018) are essential step in regulating the epithelial-to-mesenchyme transition (EMT) in NSCLC tumour cells and regulated metastasis. 

3. Discovery of the impact of cholesterol biosynthesis pathway in the regulation of cellular autophagy in mammalian cells 

(a) For the first time, my investigations showed that inhibition of HMG-CoA reductase induces autophagy in airway mesenchymal cells (PLOS ONE, 2011) and atrial fibroblasts (Cell Death & Disease, 2012). My investigations also showed that HMG-CoA reductase-inhibition-induced autophagy is co-regulated by unfolded protein response in these cells (BBA-Mol Cell Res., 2014). These discoveries opened new vision on the mechanisms that statins control asthma symptoms. 

(b) My team has discovered that inhibition of HMG-CoA reductase in GBM tumour cells is involved in the sensitization of these cells to temozolomide-induced apoptosis (FEBS J, 2020, Cells, 2021, Biology, 2023) and potentially could control Temozolomide chemoresistance (Nature Comm, 2022, under revision). 

4. Development of methods for autophagy detection 

The detection and interpretation of autophagy have always been a challenge for scientists. In addition to the standards for chemical inhibition of autophagy described above, my team also recently developed autophagy detection protocols that can be widely used by scientists who are investigating autophagy. My trainees have been actively involved in this, which I consider an important part of their research training.

(a) We developed a unique and sensitive method for mitophagy in lung adenocarcinoma cells (Methods Mol Biol 2024). 

(b) We also developed the first-ever protocol for the detection of autophagy in the 3D culture of ARMS, ERMS and GBM cells (MethodsX 2021, IJMS 2020, (Methods Mol Biol 2024), which will be of benefit to both cancer biologists and bioengineers who are doing a high-throughput screening of chemical compounds and their effects on cell viability.

(c) My lab discovered the impact of Bafilomycin A1, as an inhibitor of autophagy flux, on cellular phenotype. This discovery was highlighted in the Autophagy Guidelines published in 2016 and 2021, and BafA1 is now widely used by the autophagy research community. 

(d) We developed a unique and sensitive method for autophagy detection in the Leishmania parasite (Methods Mol Biol 2024). 

(e) We developed a unique and sensitive method for autophagy detection in conjunctivitis fibroblasts (Methods Mol Biol 2024). 

(f) We developed a unique and sensitive method for autophagy detection in gingival epithelial cells (Methods Mol Biol 2024).

(g) We developed a unique and sensitive method for the evaluation of the impact of stiffness in autophagy in the ERMS tumour cells (Methods Mol Biol 2024).

(i) My team co-developed (with Dr. Salimi’s group, Bioengineering) a method to determine autophagy flux using lens-less optical DIELECTROPHORESIS BASED MICRO cytometry. The method is based on the interaction of an electric field with a cell. Depending on the number of autophagosomes, the DEP force moves the cells closer to or farther away from the electrodes. This method will provide opportunities for cell biologists to measure the flux of autophagy without using any chemicals, or antibodies, enable them to avoid false positive and negative results, and avoid the high cost of antibody or TEM detection methods.

(j) My lab introduces a novel, cost-effective, non-fluorescent immunohistochemistry (IHC) method for evaluating autophagy flux. This technique, based on antigen-antibody reactions and chromogenic detection, provides clear, quantifiable results under standard light microscopy, eliminating the need for expensive equipment and specialized reagents. Our method simplifies technical requirements, making it accessible to routine clinical laboratories and research settings with limited resources. By comparing our approach with traditional fluorescence methods, we demonstrate its superior effectiveness, cost-efficiency, and applicability to patient samples. This innovative technique has the potential to significantly advance autophagy research and improve clinical diagnostics, offering a practical and robust tool for studying autophagy mechanisms in diseases such as cancer and neurodegenerative disorders. Our non-fluorescent IHC method represents a significant step forward in evaluating autophagy flux, making it more accessible and reliable, with the promise of enhancing our understanding and treatment of autophagy-related diseases (FEBSOPEN-24-0361).

5. Discovery of the role of autophagy in the regulation of the response of tumour cells to S100A8/A9

S100A8/A9 is a neutrophil protein which is involved in the regulation of tumour microenvironment in different cancers. My investigations showed that autophagy controls S100A8/A9-induced apoptosis in different types of tumour cells (Cell Res., 2010). My discovery on S100A8/A9 opened a new avenue on the anti-tumor effect of this protein and has wide application for understanding the potential role of this protein in tumor immune therapy.  

Here is the list of my books you can buy it from Amazon. If you read any of these please contact me and share your thoughts with me.

1. Road to Human Flourishing

   

Research Operating Grants Applied or will be Applied:

1. Cancer Research Society Operating Grant (Applied in February 2024) (130,000 C$): Title: UPR and ARMS: A New Therapeutic Approach targeting ARMS cellular phenotype, Co-PI, (Coverage Period: September 2024-August 2026)

   
   

2. C17 Research Network Grant Competition in Children Cancer and Blood Disorders Operating Grant (will be Applied May 2025) (120,000 C$): Title: IRE1-spliced XBP axis as a New Target for Rhabdomyosarcoma Therapy, Principal Investigator, (Coverage Period: September 2025-August 2027) 

   
   

3. CIHR Project Grant (will be Applied in October 2024) (1,100,000 C$): BCL2 family protein, BCL2L13 Regulates Non-small Cell Lung Cancer Metastasis via Mitophagy and Anoikis, Principal Investigator, (Coverage Period: April 2025-2030). 

4. OPUSA Discovery Grant (Poland) (Applied in Dec 2023) (720,000 C$): Autophagy and Ceramide Biosynthesis, (Under Review), Principle Investigator, (Coverage Period: September 2024-2030). 

   
   

Research Grants Awarded (PI or co-PI):

• Autophagy and Metastasis in Non-Small Lung Cancer: How does Autophagy Modulate Epithelial Mesenchymal Transition (PI)      

  Research Manitoba New Investigator Award , $225,000

  September 2017-August 2023

• Cholesterol and GBM Temozolomide Chemoresistance (Saeid Ghavami: PI)      

  February 2021-January 2024

   UCRP Award, $25,000

• Pre-Clinical Model for Investigation of UPR in ARMS (Saeid Ghavami: PI)      

   September 2022-December 2023

  URGP Award, $10,000

• Mitophagy and Metastasis in Non-Small Lung Cancer Mitophagy and Regulation of Non-small Cell Lung Cancer: Bcl2l13 and NSCLC Metastasis (Saeid Ghavami: PI)      

  September 2019-October 2024

   CancerCare Manitoba Foundation Award, $120,000

• Targeting the Unfolded Protein Response to Develop New Therapeutic Strategies for Rhabdomyosarcoma (Saeid Ghavami: PI)      

   September 2023-August 2026

  CHRIM Operating Grant, $50,000

• Autophagy and Asthma: How does autophagy regulate airway remolding via affecting airway  mesenchymal cells, (Co-PI) 

  National Institute for Medical Research Development (NIMAD), $100,000

  September 2017-August 2022

• Investigating the role of Mcl-1 in Temozolomide-induced cell death in Rhabdomyosarcoma Cells (PI)      

  Children Hospital Research Institute of Manitoba (CHRIM), $40,000

  September 2017-August 2019

• Therapeutic effect of Temozolomide in Rhabdomyosarcoma: how autophagy regulated Temozolomide induced Cell Death, (PI) 

  University Collaborative Research Program (URCP), $25,000

  February 2017-January 2019

• Elucidating autophagy pathways as a new therapeutic target for leukemia drug development (Co-PI) 

  National Institute for Medical Research Development (NIMAD), $55,000

  March 2015-February 2018

• Mevalonate Cascade Inhibition Sensitizes Human Glioblastoma Cells to Temozolomide via Modulation of Autophagy (PI)     

  Health Science Foundation, $70,000

  September 2016-August 2018

• How Mevalonate Cascade Inhibition Modulates TMZ induced Cell Death in glioblastoma, (Co-PI) 

  National Institute for Medical Research Development (NIMAD), $65,000

  March 2015-February 2018

• Mevalonate Cascade Inhibition Sensitizes Human Glioblastoma Cells to Temozolomide via Modulation of Autophagy (PI)      

  Mathematics of Information Technology and Complex Systems Accelerate (Mitacs Accelerate), $45,000

  February 2017-January 2018

• Autophagy as a Strategy for Modulation of Leukemic Stem Cell Differentiation/Dedifferentiation in Acute Myelocytic Leukemia (Co-PI)

  International Cooperation for Applied Research Development (ICARD), $15,000

  September 2015-August 2017

• Autophagy and EMT 

  University of Manitoba Start-up Fund, $125,000

  November 2013-October 2016

  Autophagy is a Target for Modulation of Epithelial-Mesenchymal Transition in Lung Cancer (PI)

  Manitoba Medical Service Foundation (MMSF), $21,500

  April 2015-March 2016

• Mevalonate Cascade and Glioblastoma Multiform (PI)      

  Mathematics of Information Technology and Complex Systems (Mitacs Globalink), $10,00

  April 2016-August 2016

• Autophagy is a Target for Tumor Invasion in Lung Cancer (PI)

  University Research Grants Program (URGP), $7500

  January 2015-July 2015

• Improving Breast Cancer Therapy Strategies by Inhibition of Cholesterol Biosynthesis Pathway (PI)

  Mathematics of Information Technology and Complex Systems (Mitacs Globalink) $10,000

  April 2015-August 2015

Research summary

Dr. Saeid Ghavami's research focuses on the interplay of three key cellular responses—apoptosis, autophagy, and the unfolded protein response (UPR)—in regulating cellular phenotype.

His work investigates how these cellular mechanisms contribute to lung cancer metastasis and chemotherapy response in glioblastoma and rhabdomyosarcoma.

Specifically, his research aims to understand how autophagy, UPR, and apoptosis influence metastatic phenotypes in lung cancer via Bcl2 family proteins and regulate the chemo-sensitivity of glioblastoma and rhabdomyosarcoma cells.

Research Interest

• Autophagy

• Bcl2 family proteins

• Cell phenotype

• Chemo-resistance

• Glioblastoma

• Lung cancer

• Mevalonate cascade

• Mitophagy

• Rhabdomyosarcoma

Note: In the list below, underline refers to students and postdoctoral fellows under my supervision at the University of Manitoba and Autophagy Research Centre.

• something 2024

Full-Length Manuscripts in Refereed Journals as leading author

2024

1. Da Silva Rosa Simone C, Alizadeh J, Vitorino R, Surendran A, Ravani B, Kidane B, Ghavami S*. A Lipidomics Approach to Determine the Role of Lipids and its Crosstalk with Autophagy in Lung Cancer Metastasis. 2024, Methods Mol Biol, doi: 10.1007/7651_2024_524. Online ahead of print.

2. Alizadeh J , Da Silva Rosa Simone C, Cordani M, Ghavami S*. Evaluation of Mitochondrial Phagy (Mitophagy) in Human Non-Small Adenocarcinoma Tumor Cells. 2024, Methods Mol Biol, doi: 10.1007/7651_2024_532. Online ahead of print.

3. Mehrbod P, Brun P, Rosani U, Leonardi A, Ghavami S*. Evaluation of Autophagy in conjunctival fibroblasts. 2024, Methods Mol Biol, doi: 10.1007/7651_2024_523. Online ahead of print.

4. Onwah SS, Uzzona JE, Ghavami S*. Assessment of autophagy in Leishmania parasites. 2024, Methods Mol Biol, doi: 10.1007/7651_2024_517. Online ahead of print.

5. Singh N, Ghavami S*, Chelikani P. Characterization Of Bitter Taste Receptor Dependent Autophagy in Oral Epithelial Cells. 2024, Methods Mol Biol, 10.1007/7651_2024_531. Online ahead of print.

6. Sezan S, Adiguzel S, Zareour A, Khosravi A, Gordon JW, Ghavami S*, Zarrabi A*. Assessment of Stiffness-Dependent Autophagosome Formation and Apoptosis in Embryonal Rhabdomyosarcoma Tumor Cells. 2024, Methods Mol Biol, doi: 10.1007/7651_2024_538. Online ahead of print. 

7. Behrooz AB, Cordani M, Donadelli M, Ghavami S*. Metastatic outgrowth via the two-way interplay of autophagy and metabolism. 2024, Biochim Biophys Acta Mol Basis Dis, 1870(3):166824. doi: 10.1016/j.bbadis.2023.166824. (Impact Factor 6.2, 2 citation). (Review Article)

8. Cordani M, Strippoli R, Trionfetti F, Barzegar Behrooz A, Rumio C, Velasco G, Ghavami S*, Marcucci F*. Immune checkpoints between epithelial-mesenchymal transition and autophagy: A conflicting triangle. 2024, Cancer Lett, Mar 31;585:216661. doi: 10.1016/j.canlet.2024.216661.(Impact Factor 9.2). (Review Article)

9. Behrooz AB, Cordani M, Fiore A, Donadelli M, Gordon JW, Klionsky DJ, Ghavami S*. The obesity-autophagy-cancer axis: Mechanistic insights and therapeutic perspectives. 2024, Semin Cancer Biol, Feb;99:24-44. doi: 10.1016/j.semcancer.2024.01.003. (Impact Factor 14.2, 2 citations). (Review Article).

10. Bhushan B, Iranpour R, Eshtiagh AM, da Silva Rosa SS, Lindsey BW, Gordon JE, Ghavami S*. 2024, Transforming Growth Factor Beta and Alveolar Rhabdomyosarcoma: A Challenge of Tumor Differentiation and Chemotherapy Response. 2024, IJMS, 25(5), 2791; https://doi.org/10.3390/ijms25052791. (Impact Factor 5.2, 2 citations). (Review Article).

11. Barzegar Behrooz A, Latifi-Navid H, Lotfi J, Khodagholi F, Shojaei S, Ghavami S*, Fahanik Babaei J*. CSF amino acid profiles in ICV-streptozotocin-induced sporadic Alzheimer’s disease in male Wistar rat: a metabolomics and systems biology perspective. 2024, FEBS Open Bio oi: 10.1002/2211-5463.13814. Online ahead of print. (Impact Factor 3). 

12. Singh N, Ulmer B, Medapati MR, Schroth RJ, Ghavami S*, Chelikani P*. 2024, Bitter taste receptor T2R14 and autophagy flux in gingival epithelial cells, 2024, Cells 13(6):531. doi: 10.3390/cells13060531. The article has been selected as the cover page of the volume(Impact Factor, 6.2).

13. Fathi-Karkan S, Sargazi S, Shojaei S, Farasati FarB, Mirinejad S, Cordani M, Zarrabi A, Ghavami S*. Biotin-functionalized nanoparticles: An overview of recent trends in cancer detection. 2024, Nanoscale, doi: 10.1039/d4nr00634h. Online ahead of print (Impact Factor 6.2).  (Review Article).

14. da Silva Rosa SC, Barzegar Behrooz A, Guedes S, Vitorino R, Ghavami S*. Prioritization of genes for translation: a computational approach. 2024, Expert Rev Proteomics, Apr 9:1-23. doi: 10.1080/14789450.2024.2337004. (Impact Factor 4.5, 1 citation) (Review Article). 

15. Barzegar Behrooz A, Darzi Ramandi H, Latifi-Navid H, Peymani P, Tarharoudi R, Momeni N, Sabaghpour Azarian MM, Eltonsy S, Pour-Rashidi A, Ghavami S*. 2024, Cancers, 16(11):2121. doi: 10.3390/cancers16112121. (Impact Factor 5.2).

16. Mokarram P, Ghavami S*. Autophagy unveiled: New horizons in health and disease, 2024, Biochim Biophys Acta Mol Basis Dis. 12:167289. doi: 10.1016/j.bbadis.2024.167289. Online ahead of print. (Impact Factor 6.2),

17. Dastghaib S, Shojaei S, Mostafavi-Pour Z, Sharma P, Patterson JB, Samali A, Mokarram P, Ghavami S. Correction: Dastghaib et al. Simvastatin Induces Unfolded Protein Response and Enhances Temozolomide-Induced Cell Death in Glioblastoma Cells. Cells 2020, 9, 2339. 2024, Cells, 22;13(8):722. doi: 10.3390/cells13080722. (Impact Factor 6). 

18. Jacobs J, Iranpour R, Behrooz AB, da Silva Rosa SC, Ghavami S*. The role of BCL2L13 in glioblastoma: turning a need into a target. 2024, Biochem Cell Biol., 102(2):127-134. doi: 10.1139/bcb-2023-0221. (Impact Factor 3.5, 2 citations). (Review Article).

2023

1. Davodabadi F, Sajjadi SF, Sarhadi M, Mirghasemi S, Nadali Hezaveh M, Khosravi S, Kamali Andani M, Cordani M, Basiri M, Ghavami S*. Cancer chemotherapy resistance: Mechanisms and recent breakthrough in targeted drug delivery. 2023, Eur J Paharmacol, 5;958:176013. doi: 10.1016/j.ejphar.2023.176013. (Impact Factor 5.2, 3 citations). (Review Article)

2. Hajiahmadi S, Lorzadeh S, Iranpour R, Karima S, Rajabibazl M, Shahsavari Z*  Ghavami S*. Temozolomide, Simvastatin and Acetylshikonin Combination Induces Mitochondrial Dependent Apoptosis in GBM Cells which is regulated by Autophagy. 2023, Biology (Basel), 4;12(2):302. doi: 10.3390/biology12020302. (Impact Fact 5, 12 citations).  

3. Zarrabi A, Perrin D, Kavoosi M, Sommer M, Sezen S, Mehrbod P, Bhushan B, Machaj F, Rosik J, Kawalec P, Afifi S, Bolandi SM, Koleini P, Taheri M, Madrakian T, Łos MJ, Lindsey B, Cakir N, Zarepour A, Hushmandi K, Fallah A, Koc B, Khosravi A, Ahmadi M, Logue S, Orive G, Pecic S, Gordon JW, Ghavami S*. Rhabdomyosarcoma: Current Therapy, Challenges, and Future Approaches to Treatment Strategies. 2023, Cancers (Basel), 15(21):5269. doi: 10.3390/cancers15215269. (Impact Factor 5.2, 3 citations). (Review Article).

4. Barzegar-Behrooz A, Latifi-Navid H, Nezhadi A, Świat M, Los M, Jamalpoor Z, Ghavami S*. Molecular Mechanisms of MicroRNAs in Glioblastoma Pathogenesis. 2023, BBA-Mol Cell Res, 1870(6):119482. doi: 10.1016/j.bbamcr.2023. (Impact Factor, 5.2, 2 citations). 

5. Siapoush S, Rezaei R, Alavifard H, Hatami B, Zali MR, Vosough M, Lorzadeh S, Łos MJ, Baghaei K, Ghavami S*. Therapeutic implications of targeting autophagy and TGF-β crosstalk for the treatment of liver fibrosis. 2023, Life Sciences, 15;329:121894. doi: 10.1016/j.lfs.2023.121894. (Impact Factor, 6.2, 3 citations). (Review Article).

6. Pirmoradi L, Shojaei S, Ghavami S*, Zarepour A, Zarrabi A. Autophagy and Biomaterials: A Brief Overview of the Impact of Autophagy in Biomaterial Applications. 2023, Pharmaceutics, 5;15(9):2284. doi: 10.3390/pharmaceutics15092284. (Impact Factor, 5.2, 1 citations). (Review Article). 

7. Pourzand P, Tabasi F, Fayazbakhsh F, Sarhadi S, Bahari G, Mohammadi M, Jomepour S, Nafeli M, Mosayebi F, Heravi M, Taheri M, Hashemi M, Ghavami S*. The Reticulon-4 3-bp Deletion/Insertion Polymorphism Is Associated with Structural mRNA Changes and the Risk of Breast Cancer: A Population-Based Case-Control Study with Bioinformatics. 2023, Life Science (Basel), 2;13(7):1549. doi: 10.3390/life13071549. (Impact Factor 3.3). 

8. Barzegar-Behrooz A, Latifi-Navid H, da Silva Rosa Simone C, Swiat M, Wiechec E, Vitorino C, Vitorino R, Jamalpoor Z, Ghavami S*. Integrating Multi-Omics Analysis for Enhanced Diagnosis and Treatment of Glioblastoma: A Comprehensive Data-Driven Approach, 2023 Jun 12;15(12):3158. doi: 10.3390/cancers15123158.Cancers (Impact Factor 5.2, 5 citations). 

9. Shojaei S, Taefehshokr N, Ghavami S*. Suppression of Academics and School Training in Iran during the “Woman, Life, Freedom” Revolution. 2023, Biochemistry and Cell Biology. 101(6):496-500. doi: 10.1139/bcb-2023-0100. (Impact Factor 3.5, 1 citation). 

10. Sadeghdoust M, Aligolighasemabadi F, Dehesh T, Taefehshokr N, Sadeghdoust A, Kotfis K, Hashemiattar A, Ravandi A, Aligolighasemabadi N, Vakili O, Grabarek B, Staszkiewicz R, Łos MJ, Mokarram P, Ghavami S*. The Effects of Statins on Respiratory Symptoms and Pulmonary Fibrosis in COVID-19 Patients with Diabetes Mellitus: A Longitudinal Multicenter Study. 2023, Arch Immunol Ther Exp (Warsz). 2023 Feb 28;71(1):8. doi: 10.1007/s00005-023-00672-1. (Impact Factor 3.8, 2 citations).

11. Alizadeh A, Kavoosi M, Singh N, Lorzadeh S, Ravandi A, Kidane B, Ahmed N, Mraiche F, Mowat MR, Ghavami S*, Regulation of Autophagy via Carbohydrate and Lipid Metabolism in Cancer. 2023 Apr 7;15(8):2195. doi: 10.3390/cancers15082195., Cancers (Impact Factor 5.2, 10 citations). (Review Article).

12. Alizadeh J, da Silva Rosa SC, Weng X, Jacobs J, Lorzadeh S, Ravandi A, Vitorino R, Pecic S, Stark H, Shojaei S*, Ghavami S*. Ceramides and Ceramide Synthases in Cancer: Focus on Apoptosis and Autophagy. 2023, 102(3):151337. doi: 10.1016/j.ejcb.2023.151337., European J Cell Biol. (Impact Factor 6.8, 6 citations). (Review Article).

13. Tabasi F, Eskandari E, Ghavami S*. Remembering the Legacy of Professor Mohammad Hashemi: A Pioneer in Molecular Genetic Studies in Southeast Iran (1965-2019). 2023, Biochemistry and Cell Biology, 101(5):385-387. doi: 10.1139/bcb-2023-0116.  (Impact Factor 3.5).